CN114525342A - Application of LINC02806 in diagnosis and treatment of hepatocellular carcinoma - Google Patents

Abstract

The invention discloses a biological marker for diagnosis and treatment of liver cancer, and the specific marker is LINC02806. The present invention finds for the first time that the differential expression of LINC02806 is related to the occurrence and development of liver cancer. In liver cancer patients, the expression of LINC02806 is up-regulated, suggesting that interfering with LINC02806 gene expression may become a new approach for liver cancer treatment. For further verification, it was found that reducing the expression of LINC02806 by an inhibitor could significantly reduce the proliferation of hepatoma cells and the number of colonies formed by the cells.

Description

Application of LINC02806 in the diagnosis and treatment of hepatocellular carcinoma

technical field

The invention relates to the technical field of biomedicine, in particular to the application of LINC02806 in the diagnosis and treatment of hepatocellular carcinoma.

Background technique

Liver cancer is one of the largest leading causes of cancer deaths worldwide, especially in China, where liver cancer has become one of the most common cancers due to the high infection rate of hepatitis virus. Among primary liver cancers, hepatocellular carcinoma is the most common type. Hepatitis B virus and hepatitis C virus infection remains the leading cause of hepatocellular carcinoma. Due to late diagnosis and limited treatment options, patients with liver cancer have a poor prognosis and the incidence is on the rise globally. The median survival of patients with advanced liver cancer who did not receive treatment was only 7.1 months. Tumor recurrence is a problem even after treatment. For example, recurrence occurred 5 years after surgery in nearly 70% of patients, reducing patient survival. Therefore, there is an urgent need to elucidate the molecular pathogenesis of HCC progression and to identify optimal diagnostic and therapeutic strategies, thereby contributing to the development of new diagnostic markers and therapeutic targets to improve treatment efficiency and prognosis clinically.

LncRNAs are RNA molecules that are not open reading frames, >200 nucleotides in length. Although lncRNAs have no protein-coding capacity, they are important in epigenetics and regulation of gene expression. Numerous studies have confirmed that lncRNAs are involved in brain development, embryonic development, tissue differentiation and organogenesis. Key roles of lncRNAs in a variety of human diseases including liver cancer have been seen in recent years. For example, lncRNA MAGI2-AS3 may have a protective effect on liver cancer, lncRNA-HIS is thought to promote the occurrence, proliferation and metastasis of HCC, and lncRNA-DUXAP10 plays a role in inhibiting the proliferation of liver cancer cells through microRNA-1914. This means that lncRNAs may become potentially effective biomarkers for liver cancer diagnosis and treatment.

At present, the regulatory molecular mechanism of lncRNAs in liver cancer is still in the exploratory stage. There are still many unknown lncRNAs in liver cancer that need to be studied. They play an important role in the diagnosis, prognosis and prediction of liver cancer, and provide effective treatment for targeted therapy of liver cancer. target.

SUMMARY OF THE INVENTION

In order to make up for the deficiencies of the prior art, one of the purposes of the present invention is to provide a product for diagnosing early stage liver cancer, so that patients can be treated at an early stage, thereby improving the survival rate and quality of life.

The second objective of the present invention is to provide a therapeutic method and a pharmaceutical composition to achieve precise molecular therapy of liver cancer.

The third object of the present invention is to provide a method for screening substances to be screened for the prevention or treatment of liver cancer.

In order to achieve the above object, the present invention adopts the following technical solutions:

The invention provides the application of a reagent for detecting LINC02806 in the preparation of a product for diagnosing liver cancer.

The reagents include reagents for detecting the expression level of LINC02806 by RT-PCR, real-time quantitative PCR, in situ hybridization, northern blotting, chips or high-throughput sequencing platforms.

Further, the reagent for detecting LINC02806 by real-time quantitative PCR includes at least a pair of primers for specifically amplifying LINC02806.

Further, the reagent includes:

A probe that specifically recognizes LINC02806; or

Primers that specifically amplify LINC02806.

Further, the primer sequences for specific amplification of LINC02806 are shown in SEQ ID NO.1 and SEQ ID NO.2.

The present invention provides a product for diagnosing liver cancer, the product comprising a reagent for detecting the expression level of LINC02806 in a sample.

The products include chips, preparations or kits. Wherein, the chip includes a solid-phase carrier and an oligonucleotide probe immobilized on the solid-phase carrier, and the oligonucleotide probe includes an oligonucleotide probe for LINC02806 for detecting the transcription level of LINC02806; The kit includes primers or chips for detecting the transcription level of LINC02806.

The solid phase carrier can be made of various materials commonly used in the field of gene chips, such as but not limited to nylon membranes, glass slides or silicon wafers modified with active groups (such as aldehyde groups, amino groups, etc.), unmodified glass slides, plastic slides, etc. .

The gene detection kit or gene chip of the present invention can be used to detect the expression levels of multiple genes (for example, multiple genes related to liver cancer) including the LINC02806 gene. Improve the accuracy of liver cancer diagnosis.

Further, the reagents for detecting the level of LINC02806 in the sample include:

A probe that specifically recognizes LINC02806; or

Primers that specifically amplify LINC02806.

Further, the primer sequences for specific amplification of LINC02806 are shown in SEQ ID NO.1 and SEQ ID NO.2.

The invention provides the application of LINC02806 in preparing a pharmaceutical composition for treating liver cancer.

Further, the pharmaceutical composition includes an inhibitor of LINC02806, and/or other drugs compatible with the inhibitor and pharmaceutically acceptable carriers and/or excipients, the inhibitor can inhibit LINC02806 or involve LINC02806 Expression of substances of upstream or downstream pathways.

Further, the inhibitor is siRNA against LINC02806.

When screening effective siRNA sequences, the present invention finds out the best effective fragments through a large number of alignment analysis. In a specific embodiment of the present invention, the inventors designed and synthesized a variety of siRNA sequences, and verified them by transfecting liver cancer cell lines with transfection reagents. As a result, interference molecules with better interference effect were detected, and they have SEQID The sequences shown in NO.9 and SEQ ID NO.10 were further tested at the cellular level, and the results showed that the inhibition efficiency was very high for cellular experiments.

The nucleic acid inhibitors of the present invention, such as siRNA, can be chemically synthesized or prepared by transcribing into single-stranded RNA from an expression cassette in a recombinant nucleic acid construct. Nucleic acid inhibitors, such as siRNA, can be delivered into cells using appropriate transfection reagents, or can also be delivered into cells using a variety of techniques known in the art.

Those skilled in the art will recognize that the utility of the present invention is not limited to quantifying the gene expression of any particular variant of the marker genes of the present invention. In a specific embodiment, as a non-limiting example, the marker gene LINC02806 has the sequence shown in the LINC02806 gene (NC_000001.11) currently in the international public nucleic acid sequence database GeneBank.

In the present invention, the term "probe" refers to a molecule capable of binding to a specific sequence or subsequence or other portion of another molecule. Unless otherwise indicated, the term "probe" generally refers to a polynucleotide probe capable of binding to another polynucleotide (often referred to as a "target polynucleotide") by complementary base pairing. Depending on the stringency of the hybridization conditions, a probe can bind to a target polynucleotide that lacks complete sequence complementarity to the probe. Probes can be labeled, either directly or indirectly, to include primers. Hybridization means, including, but not limited to, solution phase, solid phase, mixed phase, or in situ hybridization assays.

In the present invention, pharmaceutically acceptable carriers include (but are not limited to): diluents, excipients such as lactose, sodium chloride, glucose, urea, starch, water, etc., fillers such as starch, sucrose, etc.; Mixtures such as simple syrup, glucose solution, starch solution, cellulose derivatives, alginate, gelatin and polyvinylpyrrolidone; wetting agents such as glycerol; disintegrating agents such as dry starch, sodium alginate, laminarin powder, agar powder, Calcium carbonate and sodium bicarbonate; absorption enhancers quaternary ammonium compounds, sodium lauryl sulfate, etc.; surfactants such as polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, stearic acid monoglyceride, Cetyl alcohol, etc.; humectants such as glycerol, starch, etc.; adsorption carriers such as starch, lactose, bentonite, silica gel, kaolin and bentonite, etc.; lubricants such as talc, calcium and magnesium stearate, polyethylene glycol Alcohol, boric acid powder, etc.

In the present invention, pharmaceutical compositions can be prepared using various additives, such as buffers, stabilizers, bacteriostatic agents, isotonic agents, chelating agents, pH control agents and surfactants.

The pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, vaginally or by implanted Reservoir for drug delivery. Oral administration or injection administration is preferred. The pharmaceutical composition of the present invention may contain any commonly used non-toxic pharmaceutically acceptable carriers, adjuvants or excipients. In certain instances, pharmaceutically acceptable acids, bases or buffers can be used to adjust the pH of the formulation to increase the stability of the formulated compound or its administered dosage form. The term parenteral as used herein includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intramarinal, intralesional, and intracranial injection or infusion techniques. As long as the target tissue can be reached, the pharmaceutical composition of the present invention can be administered to the recipient by any route.

The pharmaceutical compositions of the present invention may be administered orally in any oral dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. For oral tablets, common carriers include lactose and cornstarch. A lubricant such as magnesium stearate is also typically added. For oral administration in capsule form, suitable diluents include lactose and anhydrous cornstarch. When aqueous suspensions and/or emulsions are administered orally, the active component can be suspended or dissolved in an oily phase and combined with emulsifying and/or suspending agents. If desired, some sweetening and/or flavoring and/or coloring agents may be added. Dosage unit formulations for oral administration may be microencapsulated, as appropriate. The formulations may also be prepared for prolonged or sustained release, for example, by coating or entrapping particulate material in polymers, waxes, and the like. The pharmaceutical composition of the present invention can be used to reduce the overexpression of endogenous LINC02806, and by reducing the expression of LINC02806, the liver cancer caused by the up-regulation of LINC02806 expression can be treated.

In the present invention, a compound that inhibits LINC02806 expression can be administered to a subject as naked RNA along with a delivery agent as a nucleic acid (eg, a recombinant plasmid or viral vector) comprising a sequence that inhibits LINC02806 expression. Delivery agents can be lipophilic agents, polycations, liposomes, and the like.

The pharmaceutical compositions of the present invention may further comprise one or more anticancer agents. In a specific embodiment, the pharmaceutical composition comprises at least one compound that inhibits LINC02806 gene expression and at least one chemotherapeutic agent. The chemotherapeutic agents used in the present invention include, but are not limited to: microtubule activators, alkylating agents, antineoplastic antimetabolites, platinum compounds, DNA-alkylating agents, antitumor antibiotics, antimetabolites, microtubules Protein Stabilizers, Tubulin Destabilizers, Hormone Antagonists, Topoisomerase Inhibitors, Protein Kinase Inhibitors, HMG-COA Inhibitors, CDK Inhibitors, Cyclin Inhibitors, Caspase Inhibitors, Metals Protease inhibitors, antisense nucleic acids, triple helix DNA, nucleic acid aptamers, and molecularly modified viral, bacterial and exotoxin reagents.

The medicament of the present invention can also be used in combination with other medicaments for the treatment of liver cancer, and other therapeutic compounds can be administered simultaneously with the main active ingredients, even in the same composition. The other therapeutic compounds may also be administered alone in separate compositions or in dosage forms other than the main active ingredient. Partial doses of the principal ingredient may be administered concurrently with other therapeutic compounds, while other doses may be administered alone. During the course of treatment, the dosage of the pharmaceutical composition of the present invention can be adjusted according to the severity of symptoms, the frequency of recurrence and the physiological response of the treatment regimen.

The pharmaceutical compositions of the present invention can be administered locally, and can be formulated into ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils .

The pharmaceutical compositions of the present invention may be administered in a pharmaceutically effective amount, the term "pharmaceutically effective amount" as used herein refers to a reasonable benefit/risk ratio sufficient for use in medical treatment or prevention The amount to treat or prevent the disease may depend on factors including the severity of the disease, the activity of the drug, the patient's age, weight, health, sex, the sensitivity of the patient to the drug, the time of administration of the composition of the present invention used, and the time of administration. The route and rate of excretion, duration of treatment, elements of the drug used in combination with or concomitantly with the composition of the present invention, and other elements well known in the medical arts determine the effective dosage level. The pharmaceutical composition of the present invention may be administered as a single therapeutic agent, or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. In addition, single or multiple administrations may be performed. It is important to take all of the above elements into consideration and to administer the least amount without side effects to achieve the greatest effect.

The term "treating" refers not to cure, but to slow (reduce) a targeted pathological condition or disorder or prevent recurrence. If a patient is successfully "treated" after receiving a therapeutically effective amount of a therapeutic agent, the patient exhibits an observable and/or measurable reduction or disappearance of one or more signs and symptoms of a particular disease. For example, a significant reduction in the number of cancer cells or disappearance of cancer cells, reducing tumor size; inhibiting (ie, slowing to some extent, and preferably stopping) tumor metastasis; inhibiting tumor growth to some extent; Increased time to relief of one or more symptoms associated with a particular cancer; reduced morbidity and mortality, and improved quality of life. A reduction in the signs or symptoms of the disease can be perceived by the patient. Treatment can achieve a complete response - defined as the disappearance of all signs of cancer, or a partial response - a reduction in tumor size, preferably by a ratio of more than 50%, more preferably 75%. Patients are also considered treated if they feel their disease is stable.

In the present invention, the term "sample" includes (but is not limited to) cells, tissues, organs, body fluids (blood, lymph, etc.), digestive juices, expectoration, lung bronchial washes, urine, feces, and the like. Preferably, the sample is tissue or blood.

The present invention also provides the application of LINC02806 in screening substances to be screened for preventing or treating liver cancer.

Further, the step of screening substances to be screened for preventing or treating liver cancer includes:

The substance to be screened treats a system expressing or containing the LINC02806 gene; and

detecting the expression of the LINC02806 gene in the system;

Wherein, if the substance to be screened can reduce the expression or activity of the LINC02806 gene (preferably significantly reduced, such as lower than 20%, preferably lower than 50%, more preferably lower than 80%), it indicates that the substance to be screened It is a substance to be screened for the prevention or treatment of liver cancer.

Further, the above-mentioned systems include (but are not limited to): cellular systems, subcellular systems, solution systems, tissue systems, organ systems or animal systems.

Compared with the prior art, the present invention provides a product for diagnosing early stage liver cancer, so that patients can be treated at an early stage, thereby improving the survival rate and life treatment. The present invention also provides a treatment method and a pharmaceutical composition to achieve precise molecular treatment of liver cancer. The present invention provides a method for screening substances to be screened for prevention or treatment of liver cancer, which plays an important role in the diagnosis, prognosis and prediction of liver cancer.

Description of drawings

Figure 1 shows the expression of LINC02806 in patients with liver cancer detected by QPCR;

Figure 2 shows the expression of LINC02806 in liver cancer cells detected by QPCR;

Figure 3 is a graph showing the effect of transfected siRNA on the expression of LINC02806 in HepG2 hepatoma cells using QPCR;

Figure 4 is a graph showing the effect of LINC02806 on the proliferation of HepG2 hepatoma cells using CCK8.

Detailed ways

The present invention will be described in further detail below with reference to the accompanying drawings and embodiments. The following examples are only used to illustrate the present invention and not to limit the scope of the present invention. The experimental method of unreceipted specific conditions in the embodiment, usually according to conventional conditions, such as people such as Sambrook, molecular cloning: the conditions described in the laboratory manual (New York:Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer's suggestion conditions of.

Example 1: Screening of gene markers related to liver cancer

1. Sample collection

The cancer tissues and adjacent tissues of 5 patients with liver cancer were collected, and the patients gave informed consent. All the above specimens were obtained with the consent of the organizational ethics committee.

2. Preparation of RNA samples

Use QIAGEN's tissue RNA extraction kit to extract tissue RNA, and follow the specific steps of the instructions.

3. Quality analysis of RNA samples

The concentration and purity of the extracted RNA were detected by Nanodrop2000, RNA integrity was detected by agarose gel electrophoresis, and RIN value was determined by Agilent2100. Concentration ≥200ng/μl, OD260/280 is between 1.8 and 2.2.

4. Removal of rRNA

Ribo-Zero kits were used to remove ribosomal RNA from total RNA.

5. Construction of cDNA library

The cDNA library was constructed using the Truseq RNA sample Prep Kit of Illumina, and the specific operation was carried out according to the instructions.

6. On-board sequencing

The cDNA library was sequenced using the Hiseq4000 sequencing platform, and the specific operations were carried out according to the instructions.

7. High-throughput transcriptome sequencing data analysis

The R package DESeq2 was used to perform bioinformatics analysis on the original count data, and the lncRNAs that were not easily detected were deleted. The screening criteria for differentially expressed lncRNAs were: FDR<0.05, abs(log2FC)>2.

7. Results

RNA-seq results showed that the expression level of LINC02806 in liver cancer tissues was significantly higher than that in adjacent tissues.

Example 2: QPCR sequencing to verify the differential expression of LINC02806 gene

1. Perform large-sample QPCR verification on the differential expression of LINC02806 gene. According to the sample collection method in Example 1, 50 samples of liver cancer tissue and 50 adjacent tissue samples were collected.

2. The RNA extraction steps were the same as those in Example 1.

3. Reverse transcription:

A 20 μl reaction system was used, and 1 μg of total RNA was taken from each sample as template RNA, and the following components were added to the PCR tube: DEPC water, premixed reagents, and template RNA. 37°C for 15 minutes, 50°C for 5 minutes, 98°C for 5 minutes, and maintained at 4°C.

(3) QPCR amplification test

Primers were designed according to the sequences of LINC02806 gene and housekeeping gene GAPDH, and the primer sequences were synthesized by Shanghai Shenggong. The designed primer sequences are as follows:

The primer sequences of the LINC02806 gene are:

Forward primer: 5'-CACGATCCACATCTCAGGGG-3' (SEQ ID NO.1)

Reverse primer: 5'-TCAACACACTCGGAAGAGGC-3' (SEQ ID NO.2)

The primer sequence of the housekeeping gene GAPDH is:

Forward primer: 5'-GAAAGCCTGCCGGTGACTAA-3' (SEQ ID NO.3)

Reverse primer: 5'-GCCCAATACGACCAAATCAGAG-3' (SEQ ID NO.4)

Prepare 10 μl of the following reaction system: 5 μl of SYBR Green polymerase chain reaction system, 2 μl of forward and reverse primers (5 μM) each, and 1 μl of template cDNA. All operations were performed on ice. Three parallel tubes were set for each sample, and all amplification reactions were repeated more than three times to ensure the reliability of the results. The amplification program was: 95°C for 60s, (95°C for 10s, 60°C for 30s) × 40 cycles.

Using SYBR Green as a fluorescent marker, the PCR reaction was performed on a 7500Fast fluorescence real-time quantitative PCR instrument, and the target band was determined by melting curve analysis and electrophoresis, and the ΔΔCT method was used for relative quantification.

3. Statistical methods

The experiments were repeated three times, and the results were expressed in terms of mean ± standard deviation. SPSS 18.0 statistical software was used for statistical analysis. Statistical significance was established when P<0.05.

4. Results

The results are shown in Figure 1. Compared with adjacent tissues, the expression of LINC02806 gene was up-regulated in liver cancer tissues, and the difference was statistically significant (P<0.05), which was consistent with the results of RNA-sep.

Example 3: Differential expression of LINC02806 gene in liver cancer cell lines

1. Cell culture

Human hepatoma cell lines HepG2, Huh7 and normal liver cell line HL-7702 were cultured in DMEM containing 10% fetal bovine serum and 1% P/S in an incubator at 37°C, 5% CO2, and 90% relative humidity nourish. Change the medium once every 2-3 days, and use 0.25% EDTA-containing trypsin for routine digestion and passage.

2. RNA extraction

The RNA in the cells was extracted using Qiagen's cell RNA extraction kit, and the experimental operation was carried out according to the instructions.

3. The specific steps of reverse transcription are the same as those in Example 2

4. Statistical methods

The experiments were repeated three times, and the results were expressed in terms of mean ± standard deviation. SPSS 18.0 statistical software was used for statistical analysis. Statistical significance was established when P<0.05.

5. Results

The results are shown in Figure 2. Compared with normal liver cell lines, the expression of LINC02806 gene was up-regulated in hepatoma cells HepG2 and Huh7, and the difference was statistically significant (P<0.05), which was consistent with the RNA-sep results.

Example 4 Silencing of the LINC02806 gene

1. Cell culture

The human hepatoma cell line HepG2 was cultured, and the specific operations were the same as those in Example 3.

2. siRNA design

The interfering RNA was designed according to the sequence of LINC02806, and the experiment was divided into four groups: blank control group (HepG2), negative control group (siRNA-NC) and experimental group (siRNA1, siRNA2, siRNA3). No homology. The designed siRNA sequences are shown below:

Negative control siRNA sequence (siRNA-NC):

The sense strand is 5'-AAAUCAGAGAAUAAUCUAGGA-3' (SEQ ID NO. 5),

The antisense strand is 5'-UUUAGUCUCUUAUUAGAUCCU-3' (SEQ ID NO.6);

siRNA1:

The sense strand is 5'-UAUUACUCCCCUUAUUGCGGG-3' (SEQ ID NO.7),

The antisense strand is 5'-AUAAUGAGGGGAAUAACGCCC-3' (SEQ ID NO. 8);

siRNA2:

The sense strand is 5'-UCAAUGUGUUUUUGGAAUGCA-3' (SEQ ID NO. 9),

The antisense strand is 5'-AGUUACACAAAAACCUUACGU-3' (SEQ ID NO. 10);

siRNA3:

The sense strand is 5'-AGAUACAGUAGGAAGAUGGCA-3' (SEQ ID NO. 11),

The antisense strand is 5'-UCUAUGUCAUCCUUCUACCGU-3' (SEQ ID NO.12)

The cells were seeded into a six-well cell culture plate at 2 × 105/well, and the cells were cultured in a 37°C, 5% CO2 incubator for 24 hours; in DMEM medium without double antibody and 10% FBS, transfection was performed according to lipid Transfection was carried out according to the instructions of Body Transfection Reagent 2000 (purchased from Invitrogen Company).

3. QPCR to detect the transcription level of LINC02806 gene

3.1 The specific steps for the extraction of total RNA from cells are the same as those in Example 3.

3.2 The reverse transcription steps were the same as those in Example 2.

3.3 The steps of QPCR amplification were the same as those in Example 2.

4. Statistical methods

The experiments were repeated 3 times, and the results were expressed as mean ± standard deviation. SPSS18.0 statistical software was used for statistical analysis to interfere with the difference between the LINC02806 gene expression group and the control group. A t-test was used, and it was considered statistically significant when P<0.05.

5. Results

The results are shown in Figure 3. Compared with the transfection of empty siRNA-NC, the level of LINC02806 mRNA in the experimental group decreased, and the interference effect of the siRNA2 group was the most significant, and the difference was statistically significant (P<0.05).

Example 5 CCK8 detection cell proliferation experiment

1. Cell culture and transfection steps are the same as in Example 4

2. CCK8 detects cell proliferation

1) HepG2 cells in the logarithmic growth phase were inoculated into 96-well plates, with 2 × 103 cells per well; the experiment was divided into groups (control group, siRNA-NC group, siRNA2 group), and each group had 3 duplicate wells;

2) Add 10 μl/well of CCK8 reagent after 0h, 24h, 48h and 72h of transfection respectively;

3) After 2h, use a microplate reader to detect the absorbance of A450.

3. Statistical methods

Experiments were repeated three times, and SPSS13.0 statistical software was used for statistical analysis. The difference between the two was carried out by t test, and it was considered statistically significant when P<0.05.

4. Results

The results shown in Figure 4 show that the cell growth rate of the siRNA2 group was significantly lower than that of the control group, and the difference was statistically significant (P<0.05). The above results indicated that the knockout of LINC02806 could inhibit the growth of liver cancer cells.

The description of the above embodiment is only for understanding the method and the core idea of the present invention. It should be pointed out that for those of ordinary skill in the art, without departing from the principle of the present invention, several improvements and modifications can also be made to the present invention, and these improvements and modifications will also fall within the protection scope of the claims of the present invention.

Claims (10)

1. Application of a reagent for detecting LINC02806 in preparation of a product for diagnosing liver cancer.

2. Use according to claim 1, characterized in that: the reagent comprises:

a probe that specifically recognizes LINC 02806; or

And (3) primers for specifically amplifying LINC 02806.

3. Use according to claim 2, characterized in that: the primer sequence of the specific amplification LINC02806 is shown as SEQ ID NO.1 and SEQ ID NO. 2.

4. A product for diagnosing liver cancer, which is characterized in that: the product comprises an agent for detecting the level of LINC02806 expression in a sample.

5. The product of claim 4, wherein: the product comprises a chip, a preparation or a kit.

Application of LINC02806 in preparing a pharmaceutical composition for treating liver cancer.

7. Use according to claim 6, characterized in that: the pharmaceutical composition comprises an inhibitor of LINC 02806.

8. Use according to claim 7, characterized in that: the inhibitor is siRNA directed against LINC 02806.

Application of LINC02806 in screening substances to be screened for preventing or treating liver cancer.

10. Use according to claim 9, characterized in that: the step of screening the substance to be screened for preventing or treating liver cancer comprises the following steps:

treating a system expressing or containing the LINC02806 gene by a substance to be screened; and

detecting the expression of the LINC02806 gene in the system;

wherein, if the substance to be screened can reduce the expression or activity of the LINC02806 gene, the substance to be screened is the substance to be screened for preventing or treating liver cancer.

Images